With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33821-94-2,2-(3-Bromopropoxy)tetrahydro-2H-pyran,as a common compound, the synthetic route is as follows.
Example 11; N-Cyclopropyl-3-[N-(2,2-dimethyl-1-oxoindan-5-yl)-N-(3-hydroxypropyl)amino]-4-methylbenzamidea) N-Cyclopropyl-3-[N-(2,2-dimethyl-1-oxoindan-5-yl)-N-(3-(tetrahydropyran-2-yloxy)propyl)amino]-4-methylbenzamideTo a suspension of N-cyclopropyl-3-(2,2-dimethyl-1-oxoindan-5-ylamino)-4-methylbenzamide (0.2 g, 0.57 mmol, obtained in example 2) in dry toluene (6.5 mL), sodium hydride (50 mg, 60% dispersion in oil, 1.14 mmol) and 15-crown-5 (4 mg, 0.02 mmol) were added under argon and the mixture was stirred at room temperature for 20 min. Then, 3-bromopropanol tetrahydropyranyl ether (0.13 g, 0.57 mmol) was added and the mixture was heated at 90 C. overnight. It was allowed to cool and diluted with EtOAc and saturated NaHCO3. The phases were separated and the organic phase was dried over Na2SO4. The solvent was evaporated to afford the desired compound (quantitative yield).LC-MS (method 1): tR=9.74 min; m/z=491.2 [M+H]+.
33821-94-2, The synthetic route of 33821-94-2 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; PALAU PHARMA, S.A.; US2010/222363; (2010); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics